We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

32 hedge funds and large institutions have $73.2M invested in TScan Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 1

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

145% more capital inflows, than outflows

Capital inflows: $3.19M | Capital outflows: $1.3M

14% more funds holding

Funds holding: 28 → 32 (+4)

6.94% more ownership

Funds ownership: 58.72% → 65.66% (+6.9%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
32
Holders Change
+4
Holders Change %
+14.29%
% of All Funds
0.51%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
10
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$973K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$918K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$446K
4
Morgan Stanley
Morgan Stanley
New York
+$352K
5
Northern Trust
Northern Trust
Illinois
+$133K

Top Sellers

Rank Fund Capital Flow
1
Monashee Investment Management
Monashee Investment Management
Massachusetts
-$1M
2
Renaissance Technologies
Renaissance Technologies
New York
-$303K

TCRX Hedge Fund Activity: Q3 2023 in Review

32 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q3 2023, worth a combined $73.2M — up 4.7% from $69.9M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TCRX positions and 1 closed out — a net gain of 5 holders — while 10 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, adding an estimated $973K. The largest seller was Monashee Investment Management, exiting entirely with an estimated $1M sold.

  • 32 institutional investors held TScan Therapeutics (TCRX) as of Q3 2023, up from 28 in Q2 2023.
  • Funds reported $73.2M of TScan Therapeutics stock for Q3 2023, up 4.7% quarter-over-quarter.
  • 6 funds opened new TScan Therapeutics positions in Q3 2023 and 1 closed out, a net change of +5 holders.
  • The largest TScan Therapeutics buyer in Q3 2023 was BlackRock, an estimated $973K added.
  • The largest TScan Therapeutics seller in Q3 2023 was Monashee Investment Management, an estimated $1M sold.

Based on aggregated 13F filings for Q3 2023.